China Pharma Holdings (CPHI) Total Liabilities (2010 - 2026)

China Pharma Holdings (CPHI) has reported Total Liabilities for 17 consecutive years, with $8.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Liabilities rose 16.75% year-over-year to $8.5 million; the trailing twelve-month figure through Jun 2026 stood at $8.5 million (up 16.75% YoY), and the FY2025 full-year result was $8.3 million, up 15.69% from the prior year.
• Total Liabilities advanced to $8.5 million in Q2 2026 per CPHI's latest filing, from $8.1 million in the prior quarter.
• Across five years, Total Liabilities topped out at $15.7 million in Q1 2022 and bottomed at $6.9 million in Q2 2024.
• Historically, Total Liabilities has averaged $9.7 million across 5 years, with a median of $8.4 million in 2025.
• The sharpest annual moves came in 2022 and 2024: Total Liabilities climbed 23.83% in 2022, then sank 39.63% in 2024.
• Over 5 years, Total Liabilities stood at $13.5 million in 2022, then plunged by 33.2% to $9.0 million in 2023, then slipped by 20.8% to $7.1 million in 2024, then grew by 15.69% to $8.3 million in 2025, then advanced by 3.26% to $8.5 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $8.5 million, $8.1 million, and $8.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.